Clinical trials: Readmission
Chronic Obstructive Pulmonary Disease, COPD
Nasal High Flow Therapy 30 Day Readmission Study
The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy…
- Trial name
- N3ADS (NCT02552732)
- Testing
- NHF with or without Oxygen
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 29 people
- Sponsor
- Fisher and Paykel Healthcare
Ileus
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.
- Trial name
- NCT01150760
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 7,050 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)